Neogen Europe Ltd.

www.neogeneurope.com

Neogen Europe Ltd, the European subsidiary of Neogen Corporation, is a high technology business dedicated to the development and marketing of novel diagnostic kits. These kits focus on topical concerns about the quality and safety of food and agricultural products, from the quality of seed that goes into the ground, right through the chain to the safety of fully processed food products.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Medical

NAVIGATE BIOPHARMA SERVICES, INC. LAUNCHES NEW MULTIPLEX DIGITAL PCR ASSAY FOR COMPREHENSIVE QUANTIFICATION OF UP TO 5 DIFFERENT CAR-T TRANSGENES

PRNewswire | June 02, 2023

news image

During this year's AAPS National biotechnology conference, Navigate BioPharma Services, Inc., a Novartis subsidiary and a leading provider of innovative biomarker solutions for drug development, announced the launch of its new multiplex digital PCR assays for comprehensive quantification of multiple chimeric antigen receptor (CAR) T cells, a type of cancer immunotherapy that involves genetically modifying T cells to recognize and destroy certain cancers. These assays are based on the Q...

Read More

Cell and Gene Therapy, Industrial Impact

SCIENTIST.COM ANNOUNCES THE LAUNCH OF COMPLIANCE MOBILE APP FOR IOS

Scientist.com | February 02, 2023

news image

On February 1, 2023, Scientist.com, the biopharma industry's largest R&D marketplace, announced the release of a new iOS mobile app. The app provides a new, easy-to-use, on-the-go experience for purchase request approvals and compliance. In addition, iPhone users receive untethered notifications for accepting, delegating, and clarifying requests without needing to use their computers. The result is speedier approvals and fewer delays in scientific discovery. Scientist.co...

Read More

MedTech

EVAXION BIOTECH IDENTIFIES GONORRHEA AS SECOND BACTERIAL PRODUCT TARGET

Evaxion Biotech | July 04, 2022

news image

The clinical-stage biotechnology company Evaxion Biotech A/S which specializes in the creation of AI-driven immunotherapies, said today that it has chosen gonorrhea as its second bacterial target for the Company's EVX-B2 vaccine product candidate. Evaxion has opted to create a preventative vaccination against Gonorrhea, a sexually transmitted disease (STD) that has fast acquired antibiotic resistance, as its second bacterial target. Based on preliminary results in pre-clinical...

Read More

Cell and Gene Therapy

ELEVATEBIO ANNOUNCES ISSUANCE OF U.S. PATENT PROVIDING PROTECTION FOR RNA-GUIDED NUCLEASES IDENTIFIED THROUGH ITS LIFE EDIT GENE EDITING PLATFORM

ElevateBio | November 25, 2021

news image

ElevateBio, LLC, a cell and gene therapy technology company focused on powering transformative cell and gene therapies, announced that the United States Patent and Trademark Office has issued US Patent No. 11,162,114 with an anticipated expiry date of June 23, 2040, inclusive of 384 days of patent term adjustment . This patent, issued to LifeEDIT Therapeutics, Inc. is the first to provide composition and methods of use protection for various RNA-guided nucleases in Life Edit’s gene editing...

Read More
news image

Medical

NAVIGATE BIOPHARMA SERVICES, INC. LAUNCHES NEW MULTIPLEX DIGITAL PCR ASSAY FOR COMPREHENSIVE QUANTIFICATION OF UP TO 5 DIFFERENT CAR-T TRANSGENES

PRNewswire | June 02, 2023

During this year's AAPS National biotechnology conference, Navigate BioPharma Services, Inc., a Novartis subsidiary and a leading provider of innovative biomarker solutions for drug development, announced the launch of its new multiplex digital PCR assays for comprehensive quantification of multiple chimeric antigen receptor (CAR) T cells, a type of cancer immunotherapy that involves genetically modifying T cells to recognize and destroy certain cancers. These assays are based on the Q...

Read More
news image

Cell and Gene Therapy, Industrial Impact

SCIENTIST.COM ANNOUNCES THE LAUNCH OF COMPLIANCE MOBILE APP FOR IOS

Scientist.com | February 02, 2023

On February 1, 2023, Scientist.com, the biopharma industry's largest R&D marketplace, announced the release of a new iOS mobile app. The app provides a new, easy-to-use, on-the-go experience for purchase request approvals and compliance. In addition, iPhone users receive untethered notifications for accepting, delegating, and clarifying requests without needing to use their computers. The result is speedier approvals and fewer delays in scientific discovery. Scientist.co...

Read More
news image

MedTech

EVAXION BIOTECH IDENTIFIES GONORRHEA AS SECOND BACTERIAL PRODUCT TARGET

Evaxion Biotech | July 04, 2022

The clinical-stage biotechnology company Evaxion Biotech A/S which specializes in the creation of AI-driven immunotherapies, said today that it has chosen gonorrhea as its second bacterial target for the Company's EVX-B2 vaccine product candidate. Evaxion has opted to create a preventative vaccination against Gonorrhea, a sexually transmitted disease (STD) that has fast acquired antibiotic resistance, as its second bacterial target. Based on preliminary results in pre-clinical...

Read More
news image

Cell and Gene Therapy

ELEVATEBIO ANNOUNCES ISSUANCE OF U.S. PATENT PROVIDING PROTECTION FOR RNA-GUIDED NUCLEASES IDENTIFIED THROUGH ITS LIFE EDIT GENE EDITING PLATFORM

ElevateBio | November 25, 2021

ElevateBio, LLC, a cell and gene therapy technology company focused on powering transformative cell and gene therapies, announced that the United States Patent and Trademark Office has issued US Patent No. 11,162,114 with an anticipated expiry date of June 23, 2040, inclusive of 384 days of patent term adjustment . This patent, issued to LifeEDIT Therapeutics, Inc. is the first to provide composition and methods of use protection for various RNA-guided nucleases in Life Edit’s gene editing...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us